Literature DB >> 925956

Effect of the duration of infusion on the disposition of lidocaine in dogs.

J LeLorier, R Moisan, J Gagné, G Caillé.   

Abstract

Lidocaine is a commonly used and efficacious antiarrhythmic agent whose pharmacokinetics after a rapid intravenous bolus injection have been extensively studied. Due to its short half-life, a continuous infusion of lidocaine is necessary whenever therapeutic blood levels need to be maintained for prolonged periods of time. Recent work in man has shown that the elimination of lidocaine is much slower after a prolonged infusion than after a bolus. We present the results of a pharmacokinetic study of the disposition of lidocaine after the discontinuation of short (90 minutes) and long (24 hours) intravenous infusions which demonstrate that in both cases the elimination of lidocaine is best explained by a two-compartment open model with elimination from the central compartment and that the longer half-life of lidocaine after a prolonged infusion is due to an impairment of its hepatic extraction. Lidocaine hepatic elimination data obtained at the end of short- and long-term infusions confirmed the inferences drawn from the pharmacokinetic analysis by demonstrating that a long-term infusion produces an important decrease in the arterial clearance and hepatic extraction rate of lidocaine.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 925956

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  12 in total

Review 1.  Nonlinear pharmacokinetics: clinical Implications.

Authors:  T M Ludden
Journal:  Clin Pharmacokinet       Date:  1991-06       Impact factor: 6.447

2.  Effects of beta-adrenoceptor antagonists on the pharmacokinetics of lignocaine.

Authors:  G T Tucker; N D Bax; M S Lennard; S Al-Asady; H S Bharaj; H F Woods
Journal:  Br J Clin Pharmacol       Date:  1984       Impact factor: 4.335

Review 3.  Poisoning due to class 1B antiarrhythmic drugs. Lignocaine, mexiletine and tocainide.

Authors:  C P Denaro; N L Benowitz
Journal:  Med Toxicol Adverse Drug Exp       Date:  1989 Nov-Dec

4.  The pharmacokinetics and pharmacodynamics of lignocaine and MEGX in healthy subjects.

Authors:  A H Thomson; H L Elliott; A W Kelman; P A Meredith; B Whiting
Journal:  J Pharmacokinet Biopharm       Date:  1987-04

5.  Lignocaine and indocyanine green kinetics in patients following myocardial infarction.

Authors:  N D Bax; G T Tucker; H F Woods
Journal:  Br J Clin Pharmacol       Date:  1980-10       Impact factor: 4.335

6.  An enzyme-distributed system for lidocaine metabolism in the perfused rat liver preparation.

Authors:  K S Pang; J A Terrell; S D Nelson; K F Feuer; M J Clements; L Endrenyi
Journal:  J Pharmacokinet Biopharm       Date:  1986-04

7.  Time-dependent kinetics of lignocaine in the isolated perfused rat liver.

Authors:  M S Lennard; G T Tucker; H F Woods
Journal:  J Pharmacokinet Biopharm       Date:  1983-04

8.  Effect of lignocaine on arginine-vasopressin plasma levels: baseline or induced by frusemide.

Authors:  L Gariépy; P Larose; B Bailey; P du Souich
Journal:  Br J Pharmacol       Date:  1992-06       Impact factor: 8.739

Review 9.  The pharmacokinetics of lignocaine and beta-adrenoceptor antagonists in patients with acute myocardial infarction.

Authors:  S Nattel; G Gagne; M Pineau
Journal:  Clin Pharmacokinet       Date:  1987-11       Impact factor: 6.447

10.  Randomized, double-blinded, placebo controlled study of neuroprotection with lidocaine in cardiac surgery.

Authors:  Joseph P Mathew; G Burkhard Mackensen; Barbara Phillips-Bute; Hilary P Grocott; Donald D Glower; Daniel T Laskowitz; James A Blumenthal; Mark F Newman
Journal:  Stroke       Date:  2009-01-22       Impact factor: 7.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.